Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial
Titel:
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial
Auteur:
Oliveira, Mafalda Rugo, Hope S Howell, Sacha J Dalenc, Florence Cortes, Javier Gomez, Henry L Hu, Xichun Toi, Masakazu Jhaveri, Komal Krivorotko, Petr Loibl, Sibylle Morales Murillo, Serafin Okera, Meena Nowecki, Zbigniew Park, Yeon Hee Sohn, Joo Hyuk Tokunaga, Eriko Yousef, Samih Zhukova, Lyudmila Fulford, Marta Andrews, Haylee Wadsworth, Ian D'Cruz, Celina Turner, Nicholas C